NLS Pharmaceutics

87 articles about NLS Pharmaceutics

• NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering

  3/22/2024

  NLS Pharmaceutics Ltd. announced the closing of its previously announced registered direct offering of 7,000,000 of its common shares at a purchase price of $0.25 per share.

• NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering

  3/20/2024

  NLS Pharmaceutics Ltd. announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 7,000,000 of its common shares at a purchase price of $0.25 per share in a registered direct offering.

• NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform

  3/20/2024

  NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS"), a leading Swiss biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, announced today a groundbreaking exclusive worldwide license agreement (the "License Agreement") with Aexon Labs, Inc., a U.S.-based biotech firm ("Aexon").

• NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event

  3/14/2024

  NLS Pharmaceutics Ltd. today announced that Alex Zwyer, Chief Executive Officer of NLS Pharmaceutics will attend the BIO-EUROPE Springtime Partnering Event taking place March 18-20, 2024.

• Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance

  3/11/2024

  NLS Pharmaceutics Ltd. announced that it has been notified by the Listing Qualifications Department of the Nasdaq Stock Market LLC that the Company's plan to regain compliance submitted on February 23, 2024 has been approved.

• NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq - February 23, 2024

  2/23/2024

  NLS Pharmaceutics Ltd. announced that it has submitted the Company's plan, on time, to regain compliance with Nasdaq Listing Rule 5550.

• Notice of Deficiency with Nasdaq Continued Listing Requirements - January 12, 2024

  1/12/2024

  NLS Pharmaceutics Ltd. announced that on January 9, 2024, it received a letter from the Listing Qualifications staff of The Nasdaq Stock Market notifying the Company that it is no longer in compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market.

• NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.

  12/1/2023

  NLS Pharmaceutics Ltd. announced that NLS has entered into an exclusive worldwide option agreement with Aexon Labs, Inc.

• NLS Pharmaceutics Announces Election of Additional Board Members

  11/28/2023

  NLS Pharmaceutics Ltd. today announced that, subject to final approval of the extraordinary general meeting taking place on December 22, 2023, the Company's board of directors (the "Board") has elected Dr. Florence Allouche Aknin and Dr. Claudio Basetti to join the Board effective January 1, 2024.

• NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive into Narcolepsy and Idiopathic Hypersomnia

  11/27/2023

  NLS Pharmaceutics Ltd. today announced that Alex Zwyer, Chief Executive Officer of NLS Pharmaceutics, will present at the Oppenheimer Sleep Disorders Summit.

• NLS Pharmaceutics Announces Selection of Strategic Partner and Securing a Bridge Loan

  11/16/2023

  NLS Pharmaceutics Ltd. today announced that it is conducting an ongoing process to explore strategic alternatives to maximize shareholder value.

• NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification - October 25, 2023

  10/25/2023

  NLS Pharmaceutics Ltd. announced that it has received a written notice from Nasdaq Stock Market LLC indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550, which requires listed companies to maintain a minimum bid price of $1.00 per share.

• NLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions

  10/19/2023

  NLS Pharmaceutics Ltd. announced that it will postpone the company update previously scheduled for Friday, October 20, 2023, due to important developments impacting the timing of the event.

• NLS Pharmaceutics Announces Company Update on Strategic Partnerships

  10/12/2023

  NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company") today announced plans to issue an important update on discussion the company is having regarding strategic partnerships, including Timeline for the company's Phase 3 program in narcolepsy.

• NLS Pharmaceutics CEO Issues Letter to Shareholders - August 28, 2023

  8/28/2023

  NLS Pharmaceutics Ltd. announced that its Chief Executive Officer, Alex Zwyer, has issued the following letter to shareholders.

• NLS Pharmaceutics to Proceed with Phase 3 Clinical Program (AMAZE) for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study Protocol

  7/3/2023

  NLS Pharmaceutics Ltd. today announced that the U.S. Food and Drug Administration (FDA) has reviewed the full protocol for the NLS-1031 study, part of the Phase 3 program for Mazindol ER, called AMAZE.

• NLS Pharmaceutics Releases the Results from its Annual General Meeting

  6/30/2023

  NLS Pharmaceutics Ltd., a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announced that the NLS Shareholders approved all of the Board of Directors' proposals for the 2023 Annual General Meeting that took place in Zürich, Switzerland.

• NLS Pharmaceutics Company Update and Webcast Today Postponed

  6/30/2023

  NLS Pharmaceutics Ltd. today announced it will postpone its webcast previously scheduled for today due to important developments impacting the timing of the company update.

• CORRECTION FROM SOURCE: NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

  6/19/2023

  NLS Pharmaceutics Ltd. today announced that Alex Zwyer, Chief Executive Officer of NLS Pharmaceutics will present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20, 2023, at 10:30 AM ET.

• NLS Pharmaceutics Announces Company Update Webcast

  6/19/2023

  NLS Pharmaceutics Ltd. today announced plans to showcase its global strategic R&D progress and platform.